My top 10 things to watch Wednesday, Dec. 4 1. Club name Eli Lilly crushes Novo Nordisk in the first head-to-head trial comparing their obesity drugs. Club name Lilly's Zepbound generated weight loss of 20% on average after 72 weeks versus about 14% for Novo's Wegovy. Is this the end of Novo as an alternative? I don't believe Lilly has anywhere near the capacity it now needs to meet the demand . 2.
An injection pen of Zepbound, Eli Lilly’s weight loss drug, is displayed in New York City on Dec. 11, 2023.comparing their obesity drugs. Club name Lilly's Zepbound generated weight loss of 20% on average after 72 weeks versus about 14% for Novo's Wegovy. Is this the end of Novo as an alternative? I don't believe Lilly has anywhere near the capacity it now needs to meet the demand .
日本 最新ニュース, 日本 見出し
Similar News:他のニュース ソースから収集した、これに似たニュース記事を読むこともできます。
ソース: CNBC - 🏆 12. / 72 続きを読む »
ソース: CNBC - 🏆 12. / 72 続きを読む »
ソース: CNBC - 🏆 12. / 72 続きを読む »
ソース: NBCPhiladelphia - 🏆 569. / 51 続きを読む »